美沙拉嗪与益生菌联合治疗IBD患者的临床效果观察
|
摘要
目的探究对炎症性肠病(Inflammatory bowel disease,IBD)患者实施美沙拉嗪与益生菌联合治疗的效果,为临床提供指导。方法随机将2015年8月至2018年2月本院收治的102例IBD患者分为观察组(51例,应用美沙拉嗪与益生菌联合治疗)和对照组(51例,应用美沙拉嗪治疗)。对比两组患者的总有效率、炎症因子水平及不良反应发生率。结果观察组患者总有效率(98.04%)相比对照组(82.35%)明显更高,差异有统计学意义(P<0.05);观察组患者治疗后C反应蛋白(7.68±1.23)mg/L、IL-10(22.87±5.42)pg/ml相比对照组(9.89±1.65)mg/L、(32.15±8.23)pg/ml明显更低,差异有统计学意义(P<0.05);观察组患者不良反应发生率(11.76%)和对照组(13.73%),比较差异无统计学意义。结论对炎症性肠病患者实施美沙拉嗪与益生菌联合治疗的效果更佳,可有效缓解炎症反应,促进病情好转。
Objective To investigate the effect of combination therapy with mesalazine and probiotics in patients with IBD(Inflammatory bowel disease) and provide guidance for clinical practice. Methods A total of 102 patients with IBD in Japanese hospital from August 2015 to February2018 were randomly divided into observation group(51 cases, combined with mesalazine and probiotics) and control group(51 cases with mesalazine). treatment). The total effective rate, inflammatory factor levels, and incidence of adverse reactions were compared between the two groups.Results The total effective rate(98.04%) of the observation group was significantly higher than that of the control group(82.35%), and the difference was statistically significant(P<0.05). The C-reactive protein(7.68±1.23) mg/L after treatment in the observation group. IL-10(22.87±5.42) pg/ml was significantly lower than the control group(9.89±1.65) mg/L and(32.15±8.23) pg/ml, the difference was statistically significant(P<0.05);The incidence of adverse reactions in the observation group(11.76%) and the control group was 13.73%, there was not statistically significant. Conclusion The combination of mesalazine and probiotics is more effective in patients with inflammatory bowel disease, which can effectively alleviate the inflammatory response and promote the improvement of the condition.
Objective To investigate the effect of combination therapy with mesalazine and probiotics in patients with IBD(Inflammatory bowel disease) and provide guidance for clinical practice. Methods A total of 102 patients with IBD in Japanese hospital from August 2015 to February2018 were randomly divided into observation group(51 cases, combined with mesalazine and probiotics) and control group(51 cases with mesalazine). treatment). The total effective rate, inflammatory factor levels, and incidence of adverse reactions were compared between the two groups.Results The total effective rate(98.04%) of the observation group was significantly higher than that of the control group(82.35%), and the difference was statistically significant(P<0.05). The C-reactive protein(7.68±1.23) mg/L after treatment in the observation group. IL-10(22.87±5.42) pg/ml was significantly lower than the control group(9.89±1.65) mg/L and(32.15±8.23) pg/ml, the difference was statistically significant(P<0.05);The incidence of adverse reactions in the observation group(11.76%) and the control group was 13.73%, there was not statistically significant. Conclusion The combination of mesalazine and probiotics is more effective in patients with inflammatory bowel disease, which can effectively alleviate the inflammatory response and promote the improvement of the condition.
引文
[1]李燕飞,杨剑,徐舒佳,等.美沙拉嗪联合益生菌对炎症性肠病的疗效及血清炎性因子的影响[J].国际消化病杂志,2018,38(1):67-70.
[2]尹明明,施嫣红,沈蓉蓉,等.益生菌改善炎症性肠病患者的临床疗效和肠屏障功能观察[J].中国微生态学杂志,2017,29(4):427-430.
[3]郭江芳.肠道益生菌辅助美沙拉嗪治疗炎症性肠病的临床效果[J].深圳中西医结合杂志,2017,27(22):87-88.
[4]廖煜,杨天文.双歧杆菌三联活菌联合美沙拉嗪治疗中国炎症性肠病患者疗效及安全性的Meta分析[J].山西医科大学学报,2018,49(2):140-147.
[5]季雪良,陈光兰,汪望月,等.炎症性肠病患者临床分析[J].浙江临床医学,2017,19(1):98-99,102.
[6]高镨月,张爱军.美沙拉嗪治疗炎症性肠病的疗效与作用机制分析[J].中国医学创新,2017,14(35):138-141.
[7] Yang Qing fan, Chen Bai li, Zhang Qing sen, et al.Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population[J]. Journal of digestive diseases, 2015,16(1):22-30.
[8]何栩,杜国平.高压臭氧灌肠联合美沙拉嗪对炎症性肠病治疗的临床效果[J].中国实用医药,2017,12(34):128-129.
[9]舒慧君,李骥,杨红,等.免疫抑制治疗对HBsAg阳性炎症性肠病患者HBV再活动的影响[J].胃肠病学和肝病学杂志,2016,25(10):1127-1131.
[10]潘芳莲.替硝唑联合美沙拉嗪治疗炎症性肠病的疗效观察[J].当代医学,2016,22(3):136-137.
[11]王腾勇,刘锦忠,张翠,等.血清抗微生物抗体检测诊断炎症性肠病的意义初步研究[J].当代医学,2017,23(24):107-109.
[12]朱益佳,宁明哲,杨平,等.血清炎症性肠病抗体谱的检测对IBD诊断及鉴别诊断的临床价值[J].现代检验医学杂志,2017,32(1):141-143.
[2]尹明明,施嫣红,沈蓉蓉,等.益生菌改善炎症性肠病患者的临床疗效和肠屏障功能观察[J].中国微生态学杂志,2017,29(4):427-430.
[3]郭江芳.肠道益生菌辅助美沙拉嗪治疗炎症性肠病的临床效果[J].深圳中西医结合杂志,2017,27(22):87-88.
[4]廖煜,杨天文.双歧杆菌三联活菌联合美沙拉嗪治疗中国炎症性肠病患者疗效及安全性的Meta分析[J].山西医科大学学报,2018,49(2):140-147.
[5]季雪良,陈光兰,汪望月,等.炎症性肠病患者临床分析[J].浙江临床医学,2017,19(1):98-99,102.
[6]高镨月,张爱军.美沙拉嗪治疗炎症性肠病的疗效与作用机制分析[J].中国医学创新,2017,14(35):138-141.
[7] Yang Qing fan, Chen Bai li, Zhang Qing sen, et al.Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population[J]. Journal of digestive diseases, 2015,16(1):22-30.
[8]何栩,杜国平.高压臭氧灌肠联合美沙拉嗪对炎症性肠病治疗的临床效果[J].中国实用医药,2017,12(34):128-129.
[9]舒慧君,李骥,杨红,等.免疫抑制治疗对HBsAg阳性炎症性肠病患者HBV再活动的影响[J].胃肠病学和肝病学杂志,2016,25(10):1127-1131.
[10]潘芳莲.替硝唑联合美沙拉嗪治疗炎症性肠病的疗效观察[J].当代医学,2016,22(3):136-137.
[11]王腾勇,刘锦忠,张翠,等.血清抗微生物抗体检测诊断炎症性肠病的意义初步研究[J].当代医学,2017,23(24):107-109.
[12]朱益佳,宁明哲,杨平,等.血清炎症性肠病抗体谱的检测对IBD诊断及鉴别诊断的临床价值[J].现代检验医学杂志,2017,32(1):141-143.